usa listing ann

Perth, 16 December 2004: Solbec Pharmaceuticals Ltd (ASX:SBP) announced today that it will
establish a Level 1 American Depositary Receipt program (ADR), appointing The Bank of New
York as its preferred depositary bank.
The implementation of a Level 1 ADR program will make Solbec more accessible to US private
investors and will provide a vehicle with which to ensure liquidity in the stock for an US investor
base. An ADR program also creates the possibility of investment by institutions that are only
permitted to buy US based securities.
n ADR is created when a broker purchases a company’s shares on the home stock market and
delivers those to the depositary’s local custodian bank, which then instructs the depositary bank,
The Bank of New York, to issue Depositary Receipts. Depositary receipts may trade freely, just
like any other security, in the over-the-counter (OTC) market.
Further information:
About Solbec
Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of
better therapies for debilitating conditions and life-threatening diseases. The company is currently
progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of
mesothelioma and malignant melanoma, and as a topical treatment for psoriasis. Solbec's two proprietary
ingredients in Coramsine™ were isolated from the fruit of a weed known as the Devil’s Apple (Solanum
linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the
immune system. In addition to human health, Coramsine™ has potential application in the areas of animal
health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final
stages of pre-commercial development and marketing.
See www.solbec.com.au
For further information, please contact
Stephen Carter
Managing Director
Solbec Pharmaceuticals Ltd
Phone +61 (08) 944 67555
Media:
Rebecca Christie
Phone: +61 (02) 9237 2800 / 0417 382 391
[email protected]